Nothing Special   »   [go: up one dir, main page]

Sobczynski et al., 2017 - Google Patents

IgA and IgM protein primarily drive plasma corona‐induced adhesion reduction of PLGA nanoparticles in human blood flow

Sobczynski et al., 2017

View PDF @Full View
Document ID
1295069086525882299
Author
Sobczynski D
Eniola‐Adefeso O
Publication year
Publication venue
Bioengineering & Translational Medicine

External Links

Snippet

The high abundance of immunoglobulins (Igs) in the plasma protein corona on poly (lactic‐ co‐glycolic) acid (PLGA)‐based vascular‐targeted carriers (VTCs) has previously been shown to reduce their adhesion to activated endothelial cells (aECs) in human blood flow …
Continue reading at aiche.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48876—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48776—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form forms of ingredients not provided for by groups A61K47/48784 - A61K47/48992, e.g. cells, cell fragments, viruses, ghosts, red blood cells, viral vectors having the pharmacologically or therapeutically active agent complexed or covalently linked to, or being themselves modified by complexation or covalent linkage by a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans

Similar Documents

Publication Publication Date Title
Sobczynski et al. IgA and IgM protein primarily drive plasma corona‐induced adhesion reduction of PLGA nanoparticles in human blood flow
Rampado et al. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials
Takeuchi et al. Molecularly imprinted nanogels acquire stealth in situ by cloaking themselves with native dysopsonic proteins
Cox et al. Evolution of nanoparticle protein corona across the blood–brain barrier
Zhao et al. Engineering of living cells with polyphenol‐functionalized biologically active nanocomplexes
Bisso et al. Nanomaterial interactions with human neutrophils
He et al. Erythroliposomes: integrated hybrid nanovesicles composed of erythrocyte membranes and artificial lipid membranes for pore-forming toxin clearance
Hannon et al. Immunotoxicity considerations for next generation cancer nanomedicines
Luk et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors
Xiong et al. Nonvasoconstrictive hemoglobin particles as oxygen carriers
Molinaro et al. Biomimetic proteolipid vesicles for targeting inflamed tissues
Caracciolo et al. Stealth effect of biomolecular corona on nanoparticle uptake by immune cells
Arifin et al. Determination of size distribution and encapsulation efficiency of liposome‐encapsulated hemoglobin blood substitutes using asymmetric flow field‐flow fractionation coupled with multi‐angle static light scattering
Gupta et al. How corona formation impacts nanomaterials as drug carriers
Kamphuis et al. Targeting of cancer cells using click-functionalized polymer capsules
Ho et al. Protein corona formed from different blood plasma proteins affects the colloidal stability of nanoparticles differently
MX2011010825A (en) Prion-free nanoparticle compositions and methods.
Mishra et al. Biotinylated methotrexate loaded erythrocytes for enhanced liver uptake.‘A study on the rat’
Sobczynski et al. Effect of anticoagulants on the protein corona-induced reduced drug carrier adhesion efficiency in human blood flow
Sobczynski et al. Plasma protein corona modulates the vascular wall interaction of drug carriers in a material and donor specific manner
Talamini et al. Organosilica cages target hepatic sinusoidal endothelial cells avoiding macrophage filtering
Wu et al. Engineered EGCG‐Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy
Weiss et al. Surface modification of spider silk particles to direct biomolecular corona formation
Liu et al. Serum albumin–peptide conjugates for simultaneous heparin binding and detection
Saikia et al. Silica nanoparticle–endothelial interaction: uptake and effect on platelet adhesion under flow conditions